(NASDAQ: ACLX) Arcellx's forecast annual revenue growth rate of 87.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Arcellx's revenue in 2025 is $35,898,000.On average, 19 Wall Street analysts forecast ACLX's revenue for 2025 to be $1,974,766,690, with the lowest ACLX revenue forecast at $1,337,385,183, and the highest ACLX revenue forecast at $4,614,265,106. On average, 18 Wall Street analysts forecast ACLX's revenue for 2026 to be $7,948,331,848, with the lowest ACLX revenue forecast at $1,699,992,407, and the highest ACLX revenue forecast at $17,447,473,096.
In 2027, ACLX is forecast to generate $13,702,285,741 in revenue, with the lowest revenue forecast at $6,913,302,457 and the highest revenue forecast at $19,749,979,819.